Rivaroxaban lyospheres prepared by a dimethyl sulfoxide-based spray-freeze-drying process.
Dimethyl sulfoxide
Dissolution-enhancement
Rivaroxaban
Spray-freeze-drying
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
05 Nov 2022
05 Nov 2022
Historique:
received:
17
06
2022
revised:
21
09
2022
accepted:
21
09
2022
pubmed:
29
9
2022
medline:
21
10
2022
entrez:
28
9
2022
Statut:
ppublish
Résumé
Spray-freeze-drying (SFD) processes are usually using aqueous solvent systems, which however, exclude the use of SFD for poorly water-soluble drugs/excipients. Here, we evaluated dimethyl sulfoxide for its suitability in formulating SFD particles (lyospheres®). Rivaroxaban was spray-freeze-dried from DMSO solutions containing polyvinyl pyrrolidone (PVP; Kollidon® 25), vinylpyrrolidone-vinyl acetate copolymer (PVP-VA; Kollidon® VA64) or polyvinyl alcohol 4-88 (PVA) forming porous lyospheres® (median particle size 250 to 350 µm). Rivaroxaban was amorphous with all three polymers, which in combination with the high porosity resulted in rapid dissolution in vitro within 10 min. Consequently, this translated in lower T
Identifiants
pubmed: 36170899
pii: S0378-5173(22)00789-X
doi: 10.1016/j.ijpharm.2022.122235
pii:
doi:
Substances chimiques
poly(vinylpyrrolidone-co-vinyl-acetate)
0
Excipients
0
Dimethyl Sulfoxide
YOW8V9698H
Rivaroxaban
9NDF7JZ4M3
Povidone
FZ989GH94E
Polyvinyl Alcohol
9002-89-5
Polyvinyls
0
Solvents
0
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122235Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jan Kozak reports financial support was provided by German Academic Exchange Service. Alf Lamprecht reports financial support was provided by French National Research Agency. Jan Kozak reports a relationship with German Academic Exchange Service that includes: funding grants. Alf Lamprecht has patent #WO2021110732 (A1) pending to University of Bonn.